Last edition
News about Global Pharma
Atezolizumab will be provided by Genentech for use in Pilatus’ clinical research; PLT012 is Pilatus’ immunomodulatory candidate.
Global Pharma | 18/08/2025 | By Abha | 259
Marksans Pharma's UK Subsidiary Relonchem Secures Multiple MHRA Approvals
Marksans Pharma's wholly owned UK subsidiary, Relonchem Ltd., has received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for Metformin Hydrochloride Relonchem Prolonged Release Tablets in three strengths—500 mg, 750 mg, and 1000 mg.
Global Pharma | 18/08/2025 | By Dineshwori | 565
Kwality Pharma Receives Registration for Anti-Cancer Drug Bleomycin 15 IU In Mexico
Kwality Pharmaceuticals has received product registration for Bleomycin 15 IU in Mexico for sale and distribution, expanding its oncology portfolio in regulated markets
Global Pharma | 18/08/2025 | By Dineshwori | 223
UK Approves Sanofi's Teplizumab to Delay Onset of Stage 3 Type 1 Diabetes
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved teplizumab (Tzield) to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D.
Global Pharma | 18/08/2025 | By Dineshwori | 275
Tonix Pharmaceuticals Secures FDA Nod for Tonmya, a First-in-Class Therapy for Fibromyalgia
Tonix Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for Tonmya (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults.
Global Pharma | 18/08/2025 | By Dineshwori | 396
Alembic Secures Final USFDA Nod for Tretinoin Cream USP, 0.025%
Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Tretinoin Cream USP, 0.025 percent, indicated for the treatment of acne vulgaris.
Global Pharma | 16/08/2025 | By Dineshwori | 694
Novo Nordisk's Wegovy Approved for Treatment of MASH in Adults with Liver Fibrosis
The US FDA has approved an additional indication for Wegovy (semaglutide 2.4 mg) for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis, according to Novo Nordisk.
Global Pharma | 16/08/2025 | By Dineshwori | 386
US-based biopharmaceutical company Precigen has received approval from the Food and Drug Administration (FDA) for its immunotherapy PAPZIMEOS (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP).
Global Pharma | 16/08/2025 | By Dineshwori | 238
Vcare, Huadong Medicine Join Forces to Commercialise JAK1 Inhibitor VC005 Tablets in China
Jiangsu Vcare Pharmatech has entered an exclusive strategic partnership with Huadong Medicine to commercialize its innovative JAK1 inhibitor VC005 tablets for autoimmune diseases in China.
Global Pharma | 16/08/2025 | By Mrinmoy Dey | 556
Shilpa Medicare Secures CDSCO Approval for NorUDCA Tablets in NAFLD Treatment
Shilpa Medicare Ltd has received approval from India's Central Drugs Standard Control Organization (CDSCO) for Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD).
Global Pharma | 16/08/2025 | By Dineshwori | 735
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy